Introduction
Gliomas are the most frequent primary brain tumors, which affect 15 000 to 17 000 Americans every year. 1 Despite clinical advances of surgery, radiation therapy and chemotherapy, these malignant tumors are almost always fatal with a median survival rate of less than a year. [2] [3] [4] This poor prognosis is related to the fact that malignant glioma cells aggressively infiltrate into normal brain tissues, making total removal of the tumor impossible, thus the tumors have high relapse rates. 5, 6 Since gliomas are highly resistant to conventional therapies, there is a need to explore novel and innovative approaches for their treatments.
For patients with thyroid cancer, the iodide concentrating activity of the thyroid tissues has allowed the use of radioiodide as an effective treatment. Since more than half of residual, recurrent or metastasized thyroid tumors can concentrate radioiodide when the tumor cells are stimulated by elevated serum thyrotropin (TSH), radioiodide (I-131) has been used to ablate post-surgical remnants and to treat residual, recurrent and metastatic disease. Many studies have confirmed that radioiodide therapy significantly improves the prognosis of the thyroid cancer patient. 7 
Viral vector-mediated gene delivery into mammalian
Correspondence: SM cells, radioiodide uptake (RAIU) activity in the cells infected with rAd-CMV-hNIS#9 or rAd-CMV-FLhNIS increases as the adenoviral MOI increases. The protein expression profile of hNIS in infected cells is generally in agreement with their RAIU activity profile. Although the expressed hNIS#9 protein appeared to have a shorter half-life than FLhNIS, hNIS#9 expression could be maintained by multiple infections in these cells. In addition, we show that hNIS can be expressed and function in a xenografted human glioma by intratumoral injection of rAd-CMV-hNIS#9. Gene Therapy (2000) 7, 740-749.
cells is very efficient and is thus being used for gene therapy. Of the available vectors, recombinant adenovirus serotype 5 (Ad5) vectors are promising for gene therapy of gliomas due to their capacity to achieve high efficiency in vivo gene transfer upon intracranial administration. 8, 9 Adenoviral particles are relatively stable and amenable to high purification and concentration. 10 The expression level of the exogenous gene by recombinant adenovirusmediated gene delivery can be easily controlled by changing multiplicity of infection (MOI).
Human Na + /I − symporter (hNIS) is the molecule that mediates the active iodide uptake from blood to thyroid follicular cells in humans. Our previous study showed that active iodide uptake can be induced in non-thyroid cells in vitro by expressing exogenous hNIS. 11 In an attempt to develop hNIS gene transfer for radioiodide therapy for patients with brain tumors, we have constructed replication-defective recombinant adenoviruses, rAd-CMV-hNIS#9 and rAd-CMV-FLhNIS. The protein encoded by hNIS#9 lacks the last 31 amino acids at the C-terminal, whereas FLhNIS encodes a full-length hNIS protein. 11 In this paper, our aim is to investigate the profiles of expression and functional activity of exogenous hNIS in U1240 and U1240Tag human glioma cells by adenovirus-mediated gene delivery in vitro. We also demonstrate that hNIS can be expressed in a xenografted human glioma tumor by intratumoral injection of rAd-CMV-hNIS#9. Thus, our study provides a basis for exploring further gene therapy strategies based on hNIS gene transfer followed by radioiodide treatment in patients with brain tumors.
Results
Radioiodide uptake activity in glioma cells infected by rAd-CMV-hNIS#9 or rAd-CMV-FLhNIS The rAd-CMV-hNIS#9 and rAd-CMV-FLhNIS adenoviruses were produced as described in Materials and methods ( Figure 1) . In order to demonstrate the function of hNIS#9 or FLhNIS in glioma cell lines after rAd-CMVhNIS#9 or rAd-CMV-FLhNIS infection, RAIU activity was measured in the infected U1240 and U1240Tag cells. In both infected U1240 and U1240Tag cells, RAIU activity increased as the adenoviral MOI increased, regardless of the recombinant virus used (Figure 2a and b) . In comparing between two cell lines, at any given dosage (MOI 1, 5, 10), RAIU activities were higher for infected U1240 cells than infected U1240Tag cells for either recombinant virus. At the same MOI (Figure 2a versus b) , RAIU activities were higher (approximately two-fold) in the glioma cells infected with rAd-CMV-FLhNIS than in those infected with rAd-CMV-hNIS#9.
The temporal profile of RAIU assay showed that the RAIU activities appeared to be maximal at 24 h after infection in cells infected with rAd-CMV-hNIS#9 ( Figure  2c ), while the RAIU activities appeared to be maximal at 36 h after infection in cells infected with rAd-CMVFLhNIS ( Figure 2d ). In glioma cells infected with rAd-CMV-hNIS#9, at 24 h after infection of MOI 10, the infected U1240 cells had an 82-fold increase in RAIU activity, while the infected U1240Tag cells had a 25-fold increase in RAIU activity, compared with their corresponding non-infected cells (Figure 2c ). In glioma cells infected with rAd-CMV-FLhNIS, at 36 h after infection of MOI 10, the infected U1240 cells had an 112-fold increase in RAIU activity compared with non-infected cells (Figure 2d) . Furthermore, the RAIU activity remained at the level of approximately 100-fold higher than the parental cells until 72-h after infection in the U1240 cells infected with rAd-CMV-FLhNIS, whereas the U1240 cells infected with rAd-CMV-hNIS#9 showed significant reduction of RAIU activity 24 h after infection ( Figure  2d ). Basal RAIU activities in non-infected U1240 cells and U1240Tag cells were approximately 1500-2000 and 3000-4000 c.p.m. per well, respectively.
Correlation of infectivity with RAIU activity
To investigate whether the higher RAIU activity found in rAd-CMV-hNIS#9 or rAd-CMV-FLhNIS-infected U1240 cells versus U1240Tag cells is due to the difference Gene Therapy in efficiency of adenovirus infection in these two cell lines, we compared the adenoviral infectivity in U1240 and U1240Tag cells using the ␤-galactosidase-expressing recombinant adenovirus (rAd-CMV-LacZ). As shown in Figure 3 , at MOI 10 of rAd-CMV-LacZ infection, about 40% of U1240 cells was stained with X-gal while only about 10% of U1240Tag cells stained with X-gal. The difference of infectivity between these two cell lines is in proportion to the difference of RAIU activities between these two cell lines following infection with rAd-CMVhNIS at MOI 10 (see Figure 2a and b) . At MOI 50, the percentage of infected U1240Tag cells increases to 80-90%, while the percentage of infected U1240 cells is close to 100% (Figure 3 ). These data suggest that the higher RAIU activity observed in rAd-CMV-hNIS infected U1240 cells than in infected U1240Tag cells is likely due to a higher efficiency of adenovirus infection in U1240 cells than U1240Tag cells.
Correlation of hNIS protein expression with RAIU activity To investigate whether the expression levels of hNIS protein correlate with RAIU activity in infected U1240 and U1240Tag cells, the expression levels of hNIS#9 protein were determined by Western blot analysis in cells infected with rAd-CMV-hNIS#9 at MOI 0, 1, 5 and 10. As shown in Figure 4 , in both U1240 and U1240Tag cells, the expression levels of hNIS#9 protein increased as the MOI of rAd-CMV-hNIS#9 increased. The expression levels of hNIS#9 protein in the infected cells ( Figure 4 ) are in general agreement with the RAIU activities of the infected cells (see Figure 2a) . It is believed that the 90 kDa band represents fully glycosylated hNIS#9 protein, while the 65 kDa band is under-glycosylated hNIS#9 protein, as previously demonstrated in Graves' thyroid samples by our laboratory. 12 Maintenance of hNIS#9 protein expression by multiple infections of rAd-CMV-hNIS#9 The temporal expression profile of hNIS#9 protein was studied by infecting the glioma cells with rAd-CMVhNIS#9 at an MOI of 10, and then harvesting membrane fractions of the infected cells at 12, 24, 48 and 72 h after infection for Western blot analysis. In both U1240 and U1240Tag cells, the highest hNIS#9 protein expression levels were observed 24 h after infection (Figure 5a ), which is in accordance with the time of maximal RAIU activity observed in infected cells (see Figure 2c) . The half-life of hNIS#9 protein expressed in both U1240 and U1240Tag cells is estimated to be approximately 22 h (Figure 5a ). However, the expression level of hNIS#9 protein can be maintained by multiple infections of rAd-CMV-hNIS#9 ( Figure 5b ). U1240 cells were initially infected with rAd-CMV-hNIS#9 at MOI of 20 on day 0, and then re-infected at MOI of 10 on day 2 and day 4. The cells were collected from days 2 to 6. For comparison, the cells exposed to a single initial viral infection were collected at day 6. As shown in Figure 5b , the expression of hNIS#9 was maintained for 6 days by multiple infections in these cells, although the expressed hNIS#9 appeared to have a short half-life.
Comparison of protein stability between hNIS#9 and FLhNIS
In order to study whether the different temporal profiles of RAIU activities between the U1240 cells infected with rAd-CMV-hNIS#9 and those infected with rAd-CMVFLhNIS (see Figure 2d ) are due to the differences in protein stability between hNIS#9 and FLhNIS, the temporal profile of the accumulation of FLhNIS protein ( Figure 5c ) was compared with that of hNIS#9 protein (Figure 5a ). It appeared that FLhNIS protein has a longer half-life (estimated approximately 40 h) than the hNIS#9 protein (estimated approximately 22 h). This finding suggests that the lack of C-terminal 31 amino acids has an effect on the protein stability of hNIS.
Iodide organification and iodide efflux in glioma cells and FRTL-5 cells
As radioiodide concentrating activity in thyroid tissues is not only contributed to by active iodide uptake but also by iodide organification, we investigated the efficiency of iodide organification in the infected glioma cells. Our in vitro iodide organification experiment showed that 5-6% of iodide was organified in infected U1240 and U1240Tag cells ( Figure 6a ). As a comparison, 10-12% of radioiodide was organified in cultured FRTL-5 rat thyroid cells. Iodide efflux was also analyzed in the rAd-hNIS-infected U1240 glioma cells and FRTL-5 cells (Figure 6b ). At 5 min after replacing the radioiodide-containing buffered HBSS with iodide-free buffered HBSS, the rAd-CMV-FLhNISinfected U1240 glioma cells had less iodide retained in the cells than FRTL-5 cells, 40% versus 60%. However, at a later time, there was no significant difference in the rate of iodide efflux between these two cells.
Intratumoral injection of rAd-CMV-hNIS#9 for hNIS function and hNIS protein expression in vivo
We used xenografted human U251 glioma tumors in nude mice to test whether hNIS can be expressed and function in vivo by intratumoral injection of rAd-CMVhNIS#9. As shown in Figure 7 , tumors injected with rAd-CMV-hNIS#9 showed as high as a 25-fold increase over spleen control in RAIU activity at 44 h after rAd-CMVhNIS#9 injection, whereas the RAIU activity in the tumors injected with saline was no different to that of the spleen. The tumor piece that had three injections of rAd-CMV-hNIS#9 (hNIS-T1) showed higher RAIU activity than the tumor pieces that had two or one injection(s) of rAd-CMV-hNIS#9 (hNIS-T2 or hNIS-T3, respectively)
Figure 3 Photomicrographs illustrating X-gal staining of glioma cells cultured on Petri dishes. U1240 or U1240Tag cells were infected with rAd-CMVLacZ at MOI of 10 or 50 and were stained by X-gal 48 h later. At MOI of 10, U1240 cells showed higher infectivity (approximately 40% cells stained) than U1240Tag cells (approximately 10% cells stained). At MOI of 50, the percentage of infected U1240Tag cells increased to 80-90%, while almost 100% of U1240 cells were infected. MOI, multiplicity of infection.

Figure 4 Western blot analysis and hNIS protein quantification from glioma cells infected with rAd-CMV-hNIS#9. Cellular membrane fractions were prepared and loaded on a 4-20% gradient SDS-PAGE gel (20 g per lane). The hNIS#9 protein was detected using a polyclonal antibody against hNIS. Signal was quantified by a Lumi-imager. The expression levels of hNIS#9 increased as the MOI of rAd-CMV-hNIS#9 increased in a dose-dependent manner. A.U., arbitrary unit (set 100 for strongest signal lane).
Gene Therapy (Figure 7 ). It is noteworthy that hNIS-T1 had RAIU activity slightly higher than that of the stomach, an extrathyroidal tissue that also has evident RAIU activity in vivo, but lower than that of the thyroid.
To demonstrate that the increase of RAIU activity in the xenograft injected with rAd-CMV-hNIS#9 is due to the increase of hNIS expression, the tumors were further subjected to immunohistochemical staining to investigate hNIS expression. The hNIS protein was detected in the xenografted human glioma injected with rAd-CMVhNIS#9 (Figure 8b ), whereas no immunostaining could be detected in the tumors injected with saline ( Figure 8a ). Figure 8c shows that tumor cells near the needle penetration site express high levels of hNIS.
Discussion
Due to cellular and molecular heterogeneity of glioma, it is likely that a cocktail strategy with multi-modal therapeutic approaches will be required to extend substantially the lifespan of patients with malignant gliomas. In this study, we aimed to explore the possibility of a new gene therapy strategy based on hNIS gene transfer followed by radioiodide treatment in brain tumors. We generated replication-defective recombinant adenoviruses containing hNIS#9 or FLhNIS by homologous recombination in the E1A-transformed 293 cells. Our data convincingly demonstrated that recombinant adenovirusmediated delivery of the hNIS gene into human glioma cell lines in vitro results in dose-dependent expression and activity of hNIS. We also performed intra-tumoral injection of rAd-CMV-hNIS#9 to mimic in vivo gene delivery of hNIS, and our data demonstrated that exogenous hNIS could be expressed and function in a xenografted human glioma by intratumoral injection of rAd-CMV-hNIS#9. This study represents an important step toward the use of in vivo direct hNIS gene transfer to facilitate radioiodide therapy for patients with brain tumor.
In addition to our study, one recent study is also in favor of the hypothesis that hNIS gene transfer will facilitate the use of radioiodide to detect and to treat non-thyroidal tumors upon efficient gene delivery of hNIS. Mandell et al 13 reported that retrovirus-mediated gene transfer of rat NIS (rNIS) in four tumor cell lines confers radioiodide concentrating activity. They showed that the cells expressing rNIS were selectively killed by accumulated radioiodide using in vitro colongenic assays (56-69% of rNIS-transduced cells versus 10-17% of parental cells). Furthermore, both Mandell et al 13 and Shimura et al 14 showed that xenografts, in sizes of larger than 1 cm in diameter, derived from stable transfectants expressing rNIS in athymic nude mice could be detected by planar image after administration of radioiodide in vivo. However, in our glioma xenograft where radioiodide uptake activity was increased by intratumoral injection of rAd-CMV-hNIS, the glioma xenograft was not visible using the 99m Tc-pertechnetate planar gamma scan performed as described in Materials and methods. Given the fact that only a limited number of cells were expressing hNIS in the glioma xenograft, it is not surprising that the glioma xenograft was not detectable. These findings are consistent with the clinical findings that while 'multiple' microlesions are detectable by I-131 scan, 'solitary' lesions are only detectable by planar I-131 scan when their sizes are larger than 1 cm in diameter. Taken together, our study suggests that a more sensitive gamma imaging method, such as SPECT imaging, 15 and a sufficient number of NISpositive tumor cells are required for a given tumor to be detectable on the gamma scan in vivo. Nevertheless, radioiodide may exert its therapeutic effect in an in situ tumor with forced expression of hNIS that may not be visible on the gamma scan.
Minimal iodide organification rates (5-6%) were found in U1240 and U1240Tag cell lines. The iodide organification rate of FRTL-5 cells (10-12%) was also determined as a comparison. 6H, iodide organification assay was performed with FRTL-5 cells maintained in media containing TSH hormone (6H). 5H → 6H, iodide organification assay was performed with FRTL-5 cells which were initially maintained in media without TSH (5H), then switched to media with TSH (6H) for 2 days. (b) I − efflux studies in rAd-FLhNIS-infected U1240 glioma cells and FRTL-5 cells. The I − efflux studies were performed as described in Materials and methods. The values of I − retained in the cells (Y axis) at the various timepoints (X axis) represent the percentage of radioactivity in the cells at time 0 min (set to 100%). At time 0, the radioactivity retained in the rAd-FLhNIS
A major goal of glioma cancer therapy is to develop a therapeutic regimen that maximizes radiation exposure to invasive tumor that are surgically unresectable and minimize toxicity to adjacent non-glioma cells. Therefore, Gene Therapy 
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specific delivery of hNIS into gliomas remains a major challenge. Recently, a vector re-targeting strategy for gliomas was reported, based on the fact that epidermal growth factor receptor (EGFR) is highly expressed in the majority of gliomas, but not in normal and mitotically quiescent neural tissues. 16 In order to target adenoviral gene transfer specifically to glioma cells, a bispecific antibody conjugate was used to ablate the binding of adenovirus to fiber receptors and retarget its binding to the EGFR. This bispecific antibody-mediated re-targeting strategy may be useful for adenovirus-mediated hNIS gene transfer to glioma tumor cells. Furthermore, alternative vectors that are engineered to target to gliomas may be designed and will be considered for future study. Finally, restricted expression of hNIS in glioma cells may be accomplished by the use of glioma-specific promoters or enhancers such as the enhancer region of the glial fibrillary acidic protein (GFAP) gene. 17 Interestingly, our data showed that the efficiency of recombinant adenoviral infection is higher in U1240 cells than in U1240Tag cells, stable transfectants of U1240 cells that express the SV40 large T antigen oncoprotein. It is known that the adenovirus entry is dependent upon several critical steps including virus attachment to cellular receptors called CAR, 18 internalization via endocytosis, endosome escape and transport of virion DNA to the cell nucleus. 19 While it is tempting to conclude that one or more of these processes are affected by the expression of SV40 large T antigen oncoprotein, it is also possible that the difference of infectivity between U1240 and U1240Tag cell is merely due to clonal effect. This suggests that the efficiency of adenoviral infection in vivo may not only vary among different tissue types but may also vary among different tumor cells in a given tumor with heterogeneity.
Once iodide is taken up into the cell, it passively leaks out of the cell unless the iodide is organified into cellular protein (such as thyroglobulin in thyroid cells). In thyroid tissues, more than 80% of accumulated radioiodide is organified in vivo. 20 It is generally believed that radioiodide organification is instrumental for the effectiveness of radioiodide ablation therapy by allowing the cells to retain radioiodide long enough to kill the cells. Our data showed that while the iodide efflux measured in vitro was not significantly different between rAd-FLhNISinfected U1240 cells and FRTL-5 cells, only 5-6% of radioiodide was organified in rAd-FLhNIS-infected U1240 cells compared with 10-12% in TSH-stimulated FRTL-5 rat thyroid cells in vitro. Following these observations, the next step should determine whether sufficient radioiodide can be retained by the glioma expressing exogenous hNIS in vivo to be clinically useful as a radiation therapy or as an imaging modality. If it is necessary to prolong the retention time of radioiodide in the gliomas expressing exogenous hNIS, possible strategies include co-infection of gliomas with recombinant adenovirus carrying thyroperoxidase and recombinant adenovirus carrying thyroglobulin.
In conclusion, our study represents an important step toward the use of in vivo direct hNIS gene transfer to facilitate radioiodide therapy for patients with brain tumor. However, many challenges, such as efficient hNIS gene transfer targeting to malignant glioma cells and sufficient radioiodide retention in vivo, need to be addressed before well-controlled experiments showing in vivo efficacy of this novel gene therapy strategy can be further pursued.
Materials and methods
Cell culture
The U1240 and U251 glioma cell lines derived from human brain glioblastomas were obtained from Dr B Westermark (University of Uppsala, Uppsala, Sweden). The cells were maintained in Eagle's MEM media supplemented with 10% calf serum (for U1240) or 10% fetal bovine serum (for U251) (Gibco-BRL, Gaithersburg, MD, USA), 10 units/ml penicillin, and 10 g/ml streptomycin. The U1240Tag cell line differs from U1240 cells in that U1240Tag cells are stable transfectants of U1240 cells expressing SV40 large T antigen oncoprotein. Thus, U1240Tag glioma cells were maintained in media also containing 100 g/ml geneticin (G418). An E1A-transformed human embryonic kidney cell line, 293 cell line, was maintained in E-MEM media (Quality Biological, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) and 2 mm l-glutamine.
Generation of the rAd-CMV-hNIS#9 and rAd-CMVFLhNIS recombinant adenoviruses
The hNIS#9 cDNA clone or the FLhNIS cDNA was used to generate the rAd-CMV-hNIS#9 or rAd-CMV-FLhNIS recombinant adenovirus vector, respectively (Figure 1) . For rAd-CMV-hNIS#9 construction, the hNIS#9 cDNA fragment in the pcDNA3 vector, along with the CMV promoter and bovine growth hormone (BGH) poly-A signal, were subcloned into the E1-deleted shuttle plasmid p⌬E1sp1A (Microbix Biosystems, Toronto, Canada), which retains the Ad5 packaging signal sequence (). The resulting p⌬E1-CMV-hNIS#9 plasmid and the Ad5 helper vector pBHGE3 (Microbix Biosystems) were then cotransfected into low passage (ϽP13) 293 cells in 100 mm dishes via a calcium phosphate method. Infectious rAd-CMV-hNIS#9 recombinant adenovirus was produced by homologous recombination in which the sequence and the CMV-hNIS#9-poly-A DNA fragment were rescued into the E1-deleted region (1.0-9.8 m.u.) of the Ad 5 genome. 293 Cells showing complete cytopathic effect were collected and lysed by repeated freeze/thaw cycles. After centrifugation (3000 r.p.m., 5 min, 4°C), the supernatants were stored at −80°C as primary viral stock. Before the viral plaque was purified, the function of the rAd-CMVhNIS#9 was confirmed by performing RAIU assay in infected Cos-7 cells. The rAd-CMV-hNIS#9 was propagated in 293 cells, further purified by gradient and isopycnic CsCl ultracentrifugation banding and dialysis. The virus stocks in 15-20% glycerol were stored at −80°C before use.
Recombinant adenovirus rAd-CMV-FLhNIS was produced following the published protocol of a bacterial homologous recombination system. 21 An adenovirus backbone vector (pAdEasy-1), an E1-deleted shuttle vector (pShuttle-CMV), and the electrocompetent BJ5183 bacteria were generously provided by Dr T-C He (Johns Hopkins Oncology Center, Baltimore, MD, USA). Briefly, the FLhNIS cDNA was subcloned into pShuttle-CMV which contains the CMV promoter and Poly-A signal. The resulting pShuttle-CMV-FLhNIS vector DNA was linearized with PmeI restriction enzyme and co-transformed with pAdEasy-1 into electrocompetent E. coli BJ5183 cells. The resulting recombinant adenoviral vector DNA, pAd-CMV-FLhNIS, was re-transformed into electrocompetent DH10B bacterial cells (Gibco BRL) to acquire a higher yield of plasmid DNA, and then transfected into 293 cells (ϽP13) via the Lipofectamine method (Gibco-BRL). Recombinant adenovirus rAd-CMV-FLhNIS was produced 7-10 days after transfection. The presence of hNIS in the recombinant adenovirus was confirmed by PCR. Further, functional activity of rAd-CMV-FLhNIS was confirmed by radioiodide uptake (RAIU) assay. The isolation and purification of recombinant adenovirus rAd-CMV-FLhNIS were done as described for the rAd-CMV-hNIS#9. Plaque purification was not necessary for the bacterial recombinant homologous system.
Adenovirus-mediated LacZ expression in vitro
To evaluate the infectivity of adenovirus in the U1240 and U1240Tag cells, cells plated in 100 mm dishes were infected with rAd-CMV-LacZ at MOI 10 or 50. Cells were washed with cold PBS 48 h after viral infection and fixed with 2% paraformaldehyde/0.2% glutaraldehyde for 15 min. To detect the expression of ␤-galactosidase, the cells were stained with 1 mg/ml X-gal overnight at 37°C. After staining, the results were photographed under an inverted microscope (Nikon/Diaphot, Tokyo, Japan) at 100 × magnification. 
Western blot analysis
Western blot analysis was performed as previously described 12 with some modifications. U1240 or U1240Tag cells (2 × 10 6 cells) were plated in 100 mm dishes 24 h before infection. The cells were incubated with rAd-CMV-hNIS#9 or rAd-CMV-FLhNIS in DMEM with 2% FBS (without antibiotics) for 1.5 h at 37°C. Infected glioma cells were harvested and homogenized in a homogenizing buffer (10 mm Tris-HCl (pH 7.5), 5 mm NaCl, 1 mm EDTA, 0.1 mm PMSF, 50 g/ml leupeptin) containing 0.25 m sucrose. The lysates were centrifuged at 700 g for 10 min at 4°C. The supernatants were further centrifuged at 200 000 g for 60-90 min at 4°C to obtain membrane fractions, which were resuspended in homogenizing buffer without sucrose and kept at −80°C until use. The membrane fractions (10 or 20 g per lane) were solubilized for 30 min at 37°C in the same volume of reducing sample buffer (0.125 m Tris-HCl (pH 6.8), 4% SDS, 10% ␤-mercaptoethanol, 20% glycerol) and subjected to 4-20% gradient or 7.5% SDS-PAGE. The proteins were transferred on to nitrocellulose filter which was then blocked with 5% nonfat dry milk in TBST buffer (10 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.1% Tween 20) at 4°C overnight. Then, Western blot analysis was performed by incubating the filter with affinity purified hNIS antibody (1:3000) in TBST containing 5% nonfat dry milk for 1 h at room temperature, followed by incubation with peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:3000) for 1 h at room temperature. The filter was then incubated with the ECL detection reagent (Amersham, Piscataway, NJ, USA) for 1 min and exposed to X-ray film. For quantification of protein expression, the blot was analyzed with a LumiImager (Bio-Rad, Hercules, CA, USA).
Iodide organification
Glioma cells (1 × 10 6 cells) were plated on 100 mm dishes 24 h before rAd-CMV-hNIS infection at MOI 10. Two days later, the cells were incubated with Na 125 I, 10 Ci per plate (1 Ci/ml) for 2 h. The organification procedure was done as described previously. 20 Briefly, the glioma cells were solubilized in 1 ml of ice-cold 0.1 m NaOH. The radioactivity of the cells was counted by a ␥-counter, and this value was referred as total iodide uptake of the cells. The cells were then subjected to TCA (5% w/v) precipitation to measure the protein-bound 125 I to evaluate iodide organification. Organified 125 I was expressed as the percentage of total iodide uptake measured before TCA precipitation.
Iodide efflux measurements
Glioma cells (1 × 10 5 cells per well) were seeded in 24-well plates 24 h before rAd-CMV-FLhNIS infection. At 24 h after infection, cells were washed with buffered HBSS described by Weiss et al 22 and incubated for 1 h at 37°C, 5.0% CO 2 with buffered HBSS (1 ml per well) containing 1.0 Ci Na 125 I and 5 m of NaI carrier. The radioactive HBSS was aspirated, cells were quickly washed twice with buffered HBSS, and 1 ml iodide-free buffered HBSS was added to the cells. After incubation for various lengths of time, the buffered HBSS was removed, the cells were then lysed and the radioactivity retained in the cells were measured as described in the RAIU section above. The average radioactivities retained in the cells at various time-points were expressed as percentage of the radioactivity present in the cells at the initiation of the efflux study (set to 100%). As a comparison, FRTL-5 cells (1 × 10 5 cells per well) in 6H media were seeded in 24-well plates at the time of plating glioma cells and iodide efflux assay was performed the same as for glioma cells.
Radioiodide accumulation (RIA) assay for in vivo animals U251 glioma cells at log-phase were harvested by trypsinization and washed with HBSS without Mg 2+ and Ca
2+
. U251 cells (1 × 10 6 cells) in 250 l of complete media plus 250 l of Matrigel (Collaborative Biomedical Products, Bedford, MA, USA) were immediately subcutaneously injected into 4-week-old nude mice. When the tumor had grown to approximately 10 mm in diameter, 5-6 months after cell injection, rAd-CMV-hNIS#9 was injected into six locations per tumor (1.2 × 10 9 p.f.u. total). As a control, saline (100 l) was injected into a tumor on the opposite flank of the same animal. Forty-three hours later, NIS functional activity in xenografted glioma tumors was assessed by measuring radioiodide accumulation (RIA), the sum total of iodide influx and efflux following 125 I − injection.
125 I − was intraperitoneally administrated to mice at 0.3 Ci per gram body weight (in 0.15 ml of PBS). Mice were killed 1 h later, and tumors and several other tissues were collected in 10% formalin to measure radioactivity using a ␥-counter (Packard Instruments). The data are presented as a fold increase in radioactivity of respective tissues, compared with spleen by the following formula: (counts of tissue of interest/mg of tissue of interest)/(counts of spleen/mg of spleen). The same tumor pieces were further processed for immunohistochemical staining.
In vivo Tc-99m scintigraphy
In an attempt to visualize in vivo RAIU activity in the rAd-hNIS-infected mouse xenograft by gamma scan, the mice used for in vivo radioiodide accumulation (RIA) assay were anesthetized with inhalation of isoflurane, and then 0.3 mCi of 99m Tc-pertechnetate ( 99m TcO − 4 ) in 0.15 ml saline was administered via the tail vein injection. Mice were placed in a prone position on a gamma camera (QRS Systems, Nuclear Medicine Diagnostic Systems, San Antonio, TX, USA) with 140 keV-high resolution collimator interfaced to a Macintosh computer-based nuclear medicine imaging system (NucLear MAC 2.9; Scientific Imaging, Littleton, CO, USA). The images were obtained 5 and 20 min after injection of 99m TcO − 4 with 2 min acquisition time.
Immunohistochemical staining of xenografted tumor
Immunohistochemical staining was performed to detect hNIS proteins in the glioblastoma tumor sections as published previously 12 with some modifications. The tissue sections were incubated with 3% H 2 O 2 in methanol for 5 min to inactivate endogenous peroxidase, and then subjected to antigen retrieval in 10 mm citric acid buffer (pH 6.0) at 94°C for 30 min. The tissue sections were incubated with the purified hNIS antibody at a 1:3000 dilution at room temperature for 1 h, followed by avidin and biotin (Dako, Carpinteria, CA, USA) blocking for 10 min each. The sections were then incubated with 1:200 dilution of biotinylated goat anti-rabbit IgG (Vector, Burlingame, CA, USA) for 20 min, streptavidin peroxidase for 10 min, and DAB substrate chromogen for 5 min. Counterstaining was performed using hematoxylin.
